Integration of bioisostere database with automatic
application and prioritisation will guide the identification of novel, high
quality compounds in drug discovery
CAMBRIDGE
and SHEFFIELD, UK, December 4th, 2012 – Optibrium and Digital Chemistry, providers
of software and database solutions for drug discovery, today announce an
agreement to collaborate on the integration of Digital Chemistry’s unique
BIOSTER™ database of precedented bioisostere replacements with Optibrium’s StarDrop™ software suite. This combination will allow drug discovery
teams to quickly identify novel, high quality compounds based on the BIOSTER
molecular transformations and prioritise these within StarDrop’s intuitive
environment that guides the design and selection of compounds with an optimal
balance of properties.
The BIOSTER database contains over
25,000 bioisostere replacements, hand-curated from the literature by Dr István
Ujváry and is distributed exclusively by Digital Chemistry. As part of the
collaboration with Optibrium, the BIOSTER database will be converted into
transformations that can be applied in StarDrop’s Nova™ module, which automatically generates new,
chemically relevant compound structures to stimulate the search for high
quality chemistry related to initial hit or lead compounds. The combined
functionality of Nova and BIOSTER will allow for the application of this comprehensive
database of precedented bioisostere replacements to generate novel structures
with a high likelihood of biological activity and synthetic accessibility.
StarDrop’s unique capabilities for multi-parameter optimisation and predictive modelling will allow efficient prioritisation
of the resulting compound ideas to identify those with the best chance of
achieving the property profile required for a successful drug.
The applications of these
technologies extend throughout the drug discovery process, including the
rigorous exploration of chemistries around early hits, scaffold hopping to
overcome issues with a lead series or to identify diverse back-up series and
protection of patent space around a candidate drug.
Matthew Segall, CEO of Optibrium
commented, “We are very pleased to announce our collaboration with Digital
Chemistry. This furthers our on-going strategy to work with other leading developers
of informatics solutions in drug discovery to provide project teams with
seamless access to the best technologies to guide the efficient discovery of
novel, high quality drugs.”
Julian Hayward, Managing Director of
Digital Chemistry added, “The deployment of BIOSTER data within a predictive
software environment fulfils a long-held ambition to enhance the usefulness of
this uniquely valuable database for the discovery of novel active compounds.
The ability to generate highly focused libraries of both ‘obvious’ and
‘non-obvious’ drug candidates in this manner, will, no doubt, be a welcome
addition to the armoury of drug discovery tools.”
István Ujváry, Managing Director of
iKem and developer of BIOSTER, concluded: “Since its conception two decades
ago, BIOSTER has strived to analyse and catalogue historically documented
fragment replacement strategies to assist medicinal and pesticide chemists in
their quest for new bioactive molecules. The sophisticated Nova module of
Optibrium’s StarDrop software suite offers an exciting new tool for navigation
through the chemical space of sets of bioisosteric and other transformations of
this unique database. I am certain that the collaboration between Optibrium and
Digital Chemistry will result in a versatile and popular new product.”
The results of this collaboration
will be available in a future version of StarDrop, expected to be released during
2013.
For further information on Optibrium
and StarDrop, please visit www.optibrium.com, contact info@optibrium.com or call +44 1223 815900.
For further information on BIOSTER or
Digital Chemistry’s other products and services, please visit www.digitalchemistry.co.uk, contact info@digitalchemistry.co.uk or call +44 113 2678667.
No comments:
Post a Comment